CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer

Cetuximab (C225), an anti-Epidermal Growth Factor receptor (EGFR) monoclonal antibody, has been widely used as a routine treatment for patients with metastatic colorectal cancer (mCRC); However, many patients who initially respond to cetuximab acquire resistance. The purpose of this study was to cha...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Am J Cancer Res
Main Authors: Gao, Lingling, Xu, Jietian, He, Guodong, Huang, Jing, Xu, Weiyue, Qin, Jie, Zheng, Peng, Ji, Meiling, Chang, Wenju, Ren, Li, Wei, Yi, Xu, Jianmin, Liang, Chunmin
Format: Artigo
Sprog:Inglês
Udgivet: e-Century Publishing Corporation 2019
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6895444/
https://ncbi.nlm.nih.gov/pubmed/31815051
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker